161. Age-Related Macular Degeneration (AMD) Agerelated macular degeneration (AMD) is a disease that affects an individual scentral vision. AMD is the most common cause of severe vision loss among http://medicalcenter.osu.edu/patientcare/healthinformation/diseasesandconditions

Skip Navigation home about us referring ... Age-Related Macular Degeneration (AMD) Age-Related Macular Degeneration (AMD) Age-Related Macular Degeneration (AMD) What is age-related macular degeneration (AMD)? Age-related macular degeneration (AMD) is a disease that affects an individual's central vision. AMD is the most common cause of severe vision loss among people over 60. Because only the center of vision is affected, people rarely go blind from this disease. However, AMD can make it difficult of read, drive, or perform other daily activities that require fine, central vision. AMD occurs when the macula, which is located in the center of the retina and provides us with sight in the center of our field of vision, begins to degenerate. With less of the macula working, central vision - which is necessary for driving, reading, recognizing faces, and performing close-up work - begins to deteriorate. What are the different types of AMD? There are two primary types of AMD: dry AMD This type of AMD is responsible for 90 percent of disease cases. While its cause is unknown, it occurs as the light sensitive cells in the macula slowly deteriorate, generally occurring in one eye at a time. wet AMD This type of AMD is responsible for 10 percent of disease cases, but accounts for 90 percent of all severe vision loss caused by either type of AMD. Wet AMD occurs when new blood vessels behind the retina start to grow beneath the retina where they leak fluid and blood and can create a large blind spot in the center of the visual field. If this happens, there is a marked disturbance of vision in a short period of time.

162. Advanced Vision Therapies -- AVT Company focused on the treatment of sightthreatening eye diseases such as age-related macular degeneration and finding a cure. http://www.avtxinc.com

The AVT Mission Macular Degeneration: Finding a Cure To be a leader in the application of gene transfer technology to the treatment and cure of the major sight threatening eye diseases with a focus on: Wet Age-Related Macular Degeneration (AMD) Diabetic Proliferative Retinopathy (DPR) Retinitis Pigmentosa (RP) Dry Age-Related Macular Degeneration The AVT Breakthrough A major limitation to the development of therapies for age-related macular degeneration and other retinal diseases is the absence of technology for the efficient delivery of therapeutics to the back of the eye. AVT has overcome this limitation . The company's core technology is a proprietary gene transfer system that is capable of delivering therapeutic proteins to the retina. Most importantly, a single treatment will provide sustained and potentially life-long therapy. Overview AVT is a biotech company focusing on cures for back-of-the-eye diseases, such as age-related macular degeneration , which have addressable markets of 10 billion dollars annually. These diseases are the leading causes of blindness in the developed world and have probably, at one point or other, touched the families and friends of most of the viewers of this website. Products The first product

163. Macular Degeneration (age Related) - Photodynamic Therapy (No. 68) Photodynamic therapy for age related macular degeneration Some common Patient Information in Audio Format macular degeneration, 6 October 2003 http://www.nice.org.uk/page.aspx?o=86772

164. Photodynamic Therapy Approved For Macular Degeneration The FDA approved Visudyne Therapy for certain types of AgeRelated MacularDegeneration (AMD) on April 12, 2000. This is the first FDA-approved medication http://depts.washington.edu/ophthweb/pdt.html

TEXT ONLY FACULTY EDUCATION PATIENT CARE ... Roger H. Johnson Macular Degeneration Prize Photodynamic Therapy Approved for the Wet -Type of Age-Related Macular Degeneration (AMD) T he FDA approved Visudyne Therapy for certain types of Age-Related Macular Degeneration (AMD) on April 12, 2000. This is the first FDA-approved medication for this devastating eye disease that has become the leading cause of legal blindness in North America and Europe. AMD is a degeneration in the part of the eye that is analogous to the film in a camera, called the retina and specifically in the area of the retina that is responsible for central vision called the macula, hence the name "Macular Degeneration." M acular degeneration is divided into two types: The dry type and the wet type. Most people lose vision as a result of the wet type of macular degeneration. It is called "wet" because abnormal blood vessels grow under the retina. These blood vessels leak fluid and blood, which cause the retina or macula to degenerate. The only other proven treatment for AMD is standard laser photocoagulation. This treatment, although effective at eliminating the abnormal blood vessels, also damages the normal structures of the retina in the overlying and immediate surrounding areas. V isudyne therapy involves an IV infusion of a special dye that is taken up preferentially in these abnormal blood vessels under the retina. A low-level laser light is shone at these blood vessels 15 minutes after the infusion has begun. The light activates the dye, causing it to block the abnormal blood vessels, but does not damage the adjacent retina. In a large clinical trial, Visudyne therapy was shown to be 34% more effective than placebo (no treatment) in maintaining a patient's current vision and in some cases resulted in improved vision. The drug was also found to be very safe, with about a one-in-a-hundred (1%) chance of having a serious problem, related to the treatment. It often takes more than one treatment to stop the leakage from these vessels. Visudyne treatments may be repeated at 3-month intervals.

165. Macular Degeneration, UPMC | University Of Pittsburgh Medical Center, Pittsburgh Information about diagnosis, treatment options, and current research for maculardegeneration from the health care experts at UPMC. http://eye.upmc.com/MacularDegeneration/

Home Macular Degeneration Macular degeneration is a chronic and progressive disorder that affects the central part of the retina and causes reduced ability to see. Macular degeneration causes a gradual loss of sharp, central vision. Read more Overview Diagnosis Treatment Options ... Contact UPMC Supplemental content provided by EBSCO Publishing Terms and Conditions

166. Tulsaworld.com Health macular degeneration photo macular degeneration is an incurable eye disease and Since many people diagnosed with macular degeneration are over age 55, http://www.tulsaworld.com/health/optomMacularDegen.asp

Friday, September 09, 2005 Extended Weather Health Home Optometry Home Amblyopia (Lazy or Weak Eye) ... QUESTIONS Macular Degeneration INTRODUCTION Macular degeneration is an incurable eye disease and the leading cause of blindness in people 55 and older in the United States, affecting more than 10 million Americans. Since many people diagnosed with macular degeneration are over age 55, the number of cases in the U.S. is expected to increase significantly as baby boomers age. Some people are already calling it an epidemic. Macular degeneration is caused by the deterioration of the central portion of the retina, the inside back layer of the eye that records the images people see and sends them via the optic nerve from the eye to the brain. The retina's central portion, the macula, is responsible for focusing central vision in the eye and controls the ability to read, drive a car, recognize faces or colors, and see objects in fine detail. TREATMENT / PROCEDURE The root causes of macular degeneration are still unknown. There are two forms of age-related macular degeneration - wet and dry. Seventy percent of patients have the dry form, which involves thinning of the macular tissues and disturbances in its pigmentation. The wet form can involve bleeding within and beneath the retina, opaque deposits, and scar tissue. Ninety percent of all cases of legal blindness in macular degeneration patients are the result of the wet form.

167. NEJM -- Pegaptanib For Neovascular Age-Related Macular Degeneration Original Article from The New England Journal of Medicine Pegaptanib forNeovascular AgeRelated macular degeneration. http://content.nejm.org/cgi/content/short/351/27/2805

HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 351:2805-2816 December 30, 2004 Number 27 Next Pegaptanib for Neovascular Age-Related Macular Degeneration Evangelos S. Gragoudas, M.D., Anthony P. Adamis, M.D., Emmett T. Cunningham, Jr., M.D., Ph.D., M.P.H., Matthew Feinsod, M.D., David R. Guyer, M.D., for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Full Text PDF PDA Full Text PowerPoint Slide Set ... PubMed Citation ABSTRACT Background factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. Methods We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria. Intravitreous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks. The primary end point was the proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks.

168. Hospital Practice: Macular Degeneration Among patients with agerelated macular degeneration, carriers of single mutations in In the United States alone, age-related macular degeneration (AMD) http://www.hosppract.com/issues/2000/06/lewis.htm

Macular Degeneration: The Emerging Genetics RICHARD ALAN LEWIS JAMES R. LUPSKI Baylor College of Medicine Discovery of the gene responsible for a recessive, early-onset maculopathy has focused attention on a biomolecular pathway in which subtle metabolic flaws become toxic to irreplaceable retinal cells. The pathway's identification points toward specific ways of intervening. Among patients with age-related macular degeneration, carriers of single mutations in the same gene are proving to be remarkably common. Dr. Lewis is Professor of Ophthalmology, Pediatrics, Medicine, and Molecular and Human Genetics and Dr. Lupski is Cullen Professor of Molecular and Human Genetics, Professor of Pediatrics, and Director, Medical Scientist Training Program, Baylor College of Medicine, Houston. In the United States alone, age-related macular degeneration (AMD) affects at least 11 million people. Of the four major causes of vision loss in persons over age 50, it accounts for more cases than the other threecataract, glaucoma, and diabetic retinopathycombined. Apart from laser photocoagulation of the subretinal neovascularization characteristic of the disease's exudative, or wet, form, there is no known intervention. As long as the pathogenesis remains mysterious, a specific treatment seems unlikely to emerge. Our own efforts to trace the pathogenesis have been modeled on an approach now achieving success in complex human disorders ranging from breast and colon cancer to neurodegenerative illnesses such as Alzheimer's disease. Each disorder is scattered throughout the population, often with age-related occurrence. Each has, however, a clinical analogue with a similar or even indistinguishable phenotype except for an earlier onset and occurrence only in certain families, within which it exhibits an inheritance pattern suggestive of a single-gene disease. In such families, modern genetic research techniques may identify a disease-related gene. Identification of the protein that the gene encodes may then give access to upstream and downstream molecules delineating the biologic pathways in which the protein is involvedpathways whose malfunction produces the inherited disease and that may hold at least part of the explanation for the more common, apparently uninherited cases as well.

169. THE MERCK MANUAL--SECOND HOME EDITION, Macular Degeneration (Age-Related) In Ch. Agerelated macular degeneration affects older people and is equally common There are two forms of age-related macular degeneration, dry (atrophic) and http://www.merck.com/mmhe/sec20/ch234/ch234b.html

var externalLinkWarning = "The link you have selected will take you to a site outside Merck and The Merck Manuals.*n*nThe Merck Manuals do not review or control the content of any non-Merck site. The Merck Manuals do not endorse and are not responsible for the accuracy, content, practices, or standards of any non-Merck sources."; Search The Second Home Edition , Online Version Search Index A B C D ... Z Sections Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders ... Women's Health Issues Resources Anatomical Drawings Multimedia Pronunciations Weights and Measures ... , Online Version Section Eye Disorders Chapter Retinal Disorders Topics Introduction Blockage of Central Retinal Arteries and Veins Cancers Affecting the Retinal Detachment of the Retina ... Hypertensive Retinopathy Macular Degeneration (Age-Related) Macular Pucker Retinitis Pigmentosa Macular Degeneration (Age-Related) Buy The Book Print This Topic Email This Topic Pronunciations angiography choroid endophthalmitis macula ... retinopathy Age-related macular degeneration (age-related maculopathy) causes progressive damage to the macula, the central and most vital area of the retina, resulting in gradual loss of vision. Age-related macular degeneration affects older people and is equally common in men and women; it is more common in fair-skinned people and in those who smoke. The cause is unknown, but the condition tends to run in families.

170. Age-related Macular Degeneration Definition - Medical Dictionary Definitions Of Online Medical Dictionary and glossary with medical definitions. http://www.medterms.com/script/main/art.asp?articlekey=18726

171. Breakthroughs In Treating Macular Degeneration But the optometrist thought I had macular degeneration in my left eye, Dr.Ciulla macular degeneration is a very specific condition in which we see http://www.satevepost.org/issues/2005/0102/445017.shtml

Subscribe to The Saturday Evening Post today and save 33% off the cover price. Subscribe Message Board ... Museum Gift Shoppe Search Archives Departments Health / Fitness Food / Recipes Books / Reviews Humor / Cartoons ... Features Magazine Current Issue Subscribe Online Advertise Resources Post Blog Message Boards E-mail Newsletter Letter to Editor ... Reprint Article Breakthroughs In Treating Macular Degeneration Once considered untreatable, age-related macular degeneration (AMD) is yielding exciting "insights" into methods of prevention and promising new treatments. An interview with Thomas Ciulla, M.D. By Patrick Perry Published January/February 2005 "I didn't know what was happening," recalls 75-year-old June Simmons, who first noticed symptoms of age-related macular degeneration (AMD) in 2000. "Everything began to look funny, people weren't straight, appearing at odd angles, and cars had curves where there really weren't any." During a trip to Wal-Mart, she dropped into the optical department. "I thought perhaps I just needed stronger glasses," the outgoing and active senior recalls. "But the optometrist thought I had macular degeneration in my left eye, so he referred me to a retinal specialist."

172. Schepens Eye Research Institute The Schepens Eye Research Institute is the largest independent eye researchinstitute in America. The research conducted at The Schepens has contributed http://www.theschepens.org/

Viewing Options Contact Directions Site Map Search The Schepens Eye Research Institute is the largest independent eye research institute in America. The research conducted at The Schepens has contributed greatly to the body of knowledge embraced by the visual sciences, and has had a major impact on ophthalmic practice internationally. Contact Eye Disease Information and Resources Giving to The Schepens News and Events ... Privacy+Legal Site Created by BigBad, Inc. Peter Mallen

173. MD Support MD Support has moved to a new server. If you are not automatically redirectedwithin 5 seconds, please click here. Visit MD Support. Thank you. http://members.aol.com/danlrob/MDpeople/

window.location.replace("http://www.mdsupport.org"); MD Support has moved to a new server. If you are not automatically redirected within 5 seconds, please click here: Visit MD Support Thank you.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 9     161-173 of 173    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9